Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
TOKYO, Feb 28, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated foContinue Reading